Mood effects of antiepileptic drugs

Epilepsy and Behavior

Volumn 5, Issue SUPPL. 1, 2004, Pages 66-76

  Reijs, Rianne ^a   Aldenkamp, Albert P ^a,b   De Krom, Marc ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

Author keywords

Affective disorders and epilepsy; Mood and epilepsy; Mood effects and antiepileptic drugs; Psychiatry and epilepsy; Side effects of antiepileptic drugs

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

AGITATION; ANGER; APATHY; APLASTIC ANEMIA; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; EMOTIONAL DISORDER; EPILEPSY; FATIGUE; GABAERGIC TRANSMISSION; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; IRRITABILITY; MOOD; NERVOUSNESS; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPECTROSCOPY;

EID: 3142716685     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2003.11.009     Document Type: Article

References (86)

1. Kulig B. Meinardi H. Effects of antiepileptic drugs on motor activity and learned behavior in the rat In: Meinardi H. Rowan A.J. (Eds.) Advances in epileptology 1977 98-104 Swets & Zeitlinger Amsterdam
2. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Epilepsia 1988;29:787-93
3. Aldenkamp A.P. De Krom M. Reijs R. Newer antiepileptic drugs and cognitive issues Epilepsia 44 S4 2003 21-29
4. Ketter T.A. Post R.M. Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders Neurology 53 5, Suppl 2 1999 53-67
5. Soderpalm B. Anticonvulsants: aspects of their mechanisms of action Eur. J. Pain. 6 SA 2002 3-9
6. Harden C.L. Goldstein M.A. Mood disorders in patients with epilepsy: epidemiology and management CNS Drugs 16 2002 291-302
7. Aldenkamp A.P. Cognitive and behavioural assessment in clinical trials: when should they be done Epilepsy Res. 45 2001 155-159
8. Macdonald R.L. Kelly K.M. Antiepileptic drug mechanisms of action Epilepsia 36 S2 1995 2-12
9. Sills G.J. Brodie M.J. Update on the mechanisms of action of antiepileptic drugs Epileptic Disord. 3 2001 165-172
10. Schwarz J.R. Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of NA currents in mammalian myelinated nerve fibers Epilepsia 30 1989 286-294
11. Parnas J. Flachs H. Gram L. Psychotropic effect of antiepileptic drugs Acta Neurol. Scand. 60 1979 329-343
12. Parnas J. Gram L. Flachs H. Psychopharmacological aspects of antiepileptic treatment Prog. Neurobiol. 15 1980 119-138
13. Franks R.D. Richter A.J. Schizophrenia-like psychosis associated with anticonvulsant toxicity Am. J. Psychiatry. 136 1979 973-974
14. Ideström C.M. Schalling D. Carlquist U. Sjoqvist F. Acute effects of diphenylhydantoin in relation to plasma levels. Behavioral and psychophysiological studies Psychol. Med. 2 1972 111-120
15. Committee of Drugs. Behavioral and cognitive effects of anticonvuslant therapy. Pediatrics 1985;76:644-47
16. Houghton G.W. Richens A. Rate of elimination of tracer doses of phenytoin at different steady state serum phenytoin concentrations in epileptic patients Br. J. Clin. Pharmacol 1 1974 155-161
17. Lefkowitch M.M. Effects of diphenylhydantoin on disruptive behaviour Arch. Gen. Psychiatry 20 1969 643-651
18. Malitz S. Kanzler M. Are antidepressants better than placebo Am. J. Psychiatry 127 1971 1605-1611
19. Dalby M.A. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy Epilepsia 12 1971 325-334
20. Rodin E.A. Rim C.S. Kitano H. Lewis R. Rennick P.M. A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients J. Nerv. Ment. Dis. 163 1976 41-46
21. Dodrill C.B. Troupin A.S. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin Neurology 27 1977 1023-1028
22. Schain R.J. Ward J.W. Guthrie D. Carbamazepine as an anticonvulsant in children Neurology 27 1977 476-480
23. Trimble M.R. Thompson P.J. Anticonvulsant drugs, cognitive function and behavior Epilepsia 24 S1 1983 55-63
24. Dodrill C.B. Troupin A.S. Psychotropic effects of carbamazepine and phenytoin: a reanalysis Neurology 41 1991 141-143
25. Verma N.P. Yusko M.J. Greiffenstein M.F. Carbamazepine offers no psychotropic advantage over phenytoin in adult epileptic subjects Seizure 2 1993 53-56
26. Mathew G. Psychiatric symptoms associated with carbamazepine Br Med J (Clin Res Ed) 296 1988 1071
27. McKee R.J. Larkin J.G. Brodie M.J. Acute psychosis with carbamazepine and sodium valproate (letter) Lancet 1 1989 167
28. Fenwick P.B.C. Antiepileptic drugs and their psychotropic effects Epilepsia 33 S6 1992 33-36
29. Besag F.M. Behavioural effect of the new anticonvulsants Drug Saf. 24 2000 513-536
30. Lynn Smith W. Phillipus M.J. Guard H.L. Psychometric study of children with learning problems and 14-6 Hz positive spike EEG patterns treated with ethosuximide and placebo Arch. Dis. Child. 43 1968 616-619
31. Twyman R.E. Rogers C.J. Macdonald R.L. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital Ann. Neurol. 25 1989 213-220
32. Petroff O.A.C. Rothman D.L. Behar K.L. et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy Ann. Neurol. 39 1996 95-99
33. Ingram T.T.S. A characteristic form of overactive behaviour in brain damaged children J. Ment. Sci. 102 1986 550-558
34. Smith D.B. Mattson R.H. Cramer J.A. et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone Epilepsia 28 S3 1987 50-58
35. Vining E.P. Mellitis E.D. Dorsen M.M. et al. Psychologic and behavioral effects of antiepileptic drugs in children: a doubleblind comparison between phenobarbital and valproic acid Pediatrics 80 1987 165-174
36. Camfield C.S. Chaplin S. Doyle A. Shapiro S.H. Cummings C. Camfield P.R. Side effects of phenobarbital in toddlers; behavioural and cognitive effects J. Pediatrics 95 1979 361-365
37. Wolf S.M. Forsythe A. Behaviour disturbance, phenobarbital and febrile seizures Pediatrics 61 1978 728
38. Corbett J.A. Trimble M.R. Nichol T.C. Behavioral and cognitive impairments in children with epilepsy: the long-term effect of anticonvulsant therapy J. Am. Acad. Child Psychiat. 24 1985 17-23
39. Trimble M.R. Cull C. Children of school age: the influence of antiepileptic drugs on behavior and intellect Epilepsia 29 1988 15-19
40. Prevey M.L. Mattson R.H. Cramer J.A. Improvement in cognitive function and mood state after conversion to valproate monotherapy Neurology 39 1989 1640-1641
41. Boxer C.M. Herzberg J.L. Scott D.F. Has sodium valproate hypnotic effects? Epilepsia 17 1976 367-370
42. Sommerbeck K.W. Theilgaard A. Rasmussen K.E. Lohren V. Gram L. Wulff K. Valproate sodium: evaluation of the so-called psychotropic effect: a controlled study Epilepsia 18 1977 159-167
43. Kastner T. Finesmith R. Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation J. Clin. Psychopharmacol. 13 1993 448-451
44. Husain S.B. Wical B.S. Adverse behavioral effects of valproate therapy in children with complex partial seizures Epilepsia 39 1998 162
45. Herranz J.L. Arteaga R. Armijo J.A. Side-effects of sodium valproate in monotherapy, controlled by plasma levels: a study of 88 pediatric patients Epilepsia 23 1982 203-214
46. Kondo T. Ishida M. Kaneko S. et al. Is 2-Propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induce hyperammonia? Epilepsia 33 1992 550-554
47. Marson A.G. Kadir Z.A. Hutton J.L. Chadwick D.W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability Epilepsia 38 1997 859-880
48. Dimond K.R. Pande A.C. Lamoreus L. Pierce M.W. Effect of gabapentin (Neurotin) on mood and well-being in patients with epilepsy Prog. Neuropsychopharmacol. Biol. Psychiatry 20 1996 407-417
49. Harden C.L. Pick L.H. Alterations in mood and anxiety in epilepsy patients treated with gabapentin Epilepsia 37 1996 137
50. Mortimore C.M. Trimble M. Emmers E. Effect of gabapentin on cognition and quality of life in patients with epilepsy Seizure 7 1998 359-364
51. Dodrill C.B. Arnett J.L. Hayes A.G. et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study Epilepsy Res. 35 1999 109-121
52. Harden C.L. Lazar L.M. Pick L.H. et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin Epilepsia 40 1999 1129-1134
53. Pande A.C. Davidson J.R. Jefferson J.W. et al. Treatment of social phobia with gabapentin: a placebo-controlled study J. Clin. Psychopharmacol. 19 1999 341-348
54. Frye M.A. Ketter T.A. Kimbrell T.A. et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders J. Clin. Psychopharmacol. 20 2000 607-614
55. Leppik I.E. Tiagabine: the safety landscape Epilepsia 36 1995 10-13
56. Pereira J. Marson A.G. Hutton J.L. Tiagabine add-on for drug resistant partial epilepsy Cochrane Database Syst. Rev. 3 2002 CD001908
57. Sveinsbjornsdottir S. Sander J.W. Patsalos P.N. Upton D. Thomspon P.J. Duncan J.S. Neuropsychological effects of tiagabine, a potential new antiepileptic drug Seizure 3 1994 29-35
58. Dodrill C.B. Arnett J.L. Deaton R. Lenz G.T. Sommerville K.W. Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment and mood Epilepsy Res. 43 2000 123-132
59. Dodrill C.B. Arnett J.L. Sommerville K.W. Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy Neurology 48 1997 1025-1031
60. Leach M.J. Lees G. Riddall D.R. Lamotrigine: mechanisms of action In: Levy R.H. Mattson R.H. Meldrum B.S. (Eds.) Antiepileptic drugs 4th ed. 1995 861-869 Raven Press New York
61. Meador K.J. Loring D.W. Ray P.G. Perrine K.R. Bazquez B.R. Kalbosa T. Differential effects of carbamazepine and lamotrigine Neurology 54 Suppl 3 2000 A84
62. Aldenkamp A.P. Arends J. Bootsma H.P. et al. Randomized, double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers Epilepsia 43 2002 19-26
63. Banks G.K. Beran R.G. Neuropsychological assessment in lamotrigine treated epileptic patients Clin. Exp. Neurol. 28 1991 230-237
64. Smith D. Baker G. Davies G. Dewey M. Chadwick D.W. Outcomes of add-on treatment with lamotrigine in partial epilepsy Epilepsia 34 1993 312-322
65. Aldenkamp A.P. Mulder O.G. Overweg J. Cognitive effects of lamotrigine as first line add-on in patients with localized related (partial) epilepsy J. Epilepsy 10 1997 117-121
66. Ettinger A.B. Weisbrot D.M. Saracco J. Dhoon A. Kanner A. Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation Epilepsia 39 1998 874-877
67. Calabrese JR, Suppes T, Bowden CL, et al. for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61(11):841-50
68. Brodie MJ, Richens A, Yuen AW for the UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-9
69. Schapel G. Chadwick D. A survey comparing lamotrigine and vigabatrin in everyday clinical practice Seizure 5 1996 267-270
70. Edwards K.R. Sackellares J.C. Vuong A. Hammer A.E. Barrett P.S. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate Epilepsy Behav. 2 2001 28-36
71. Calabrese J.R. Rapport D.J. Shelton M.D. Kujawa M. Kimmel S.E. Clinical studies on the use of lamotrigine in bipolar disorder Neuropsychogobiology 38 1998 185-191
72. Bowden CL, Calabrese JR, Sachs G, et al. for the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60(4):392-400
73. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs Epilepsia 38 Suppl 1 1997 S9-17
74. Privitera M, Fincham R, Penry J, et al. for the Topiramate YE Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83
75. Faught E. Wilder B.J. Ramsay R.E. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages Neurology 46 1996 1684-1690
76. Aldenkamp A.P. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults Neurology 54 2000 270-272
77. Aldenkamp A.P. Baker G. Mulder O.G. et al. A multicentre randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures Epilepsia 41 2000 1167-1178
78. Tatum W.O. French J.A. Faught E. et al. Postmarketing experience with topiramate and cognition Epilepsia 42 2001 1134-1140
79. Shorvon S.D. Safety of topiramate: adverse events and relationship to dosing Epilepsia 37 S2 1996 18-22
80. Kahn A. Faught E. Kuzniecky R. Gilliam F. Laich E. Acute psychotic symptoms induced by topiramate Epilepsia 38 S8 1997 97
81. Crawford P. An audit of topiramate use in a general neurologic clinic Seizure 7 1998 207-211
82. Berent S. Sackellares J.C. Giordani B. Wagner J.G. Donofrio P.D. Abou-Khalil B. Zonisamide (CI-912) and cognition: results from preliminary study Epilepsia 28 1987 61-67
83. Wilensky A.J. Friel P.N. Ojemann L.M. Dodrill C.B. McCormick K.B. Levy R.H. Zonisamide in epilepsy: a pilot study Epilepsia 26 1985 212-220
84. Cramer J.A. Van Hammee G. N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam Epilepsy Behav. 4 2003 118-123
85. Post R.M. Ketter T.A. Denicoff K. et al. The place of anticonvulsant therapy in bipolar illness Psychopharmacology 128 1996 115-129
86. Guay D.R. The emerging role of valproate in bipolar disease and other psychiatric disorders Pharmacotherapy 15 1995 631-647